Your browser doesn't support javascript.
loading
The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer.
Cataldo, Maria Letizia; De Placido, Pietro; Esposito, Daniela; Formisano, Luigi; Arpino, Grazia; Giuliano, Mario; Bianco, Roberto; De Angelis, Carmine; Veneziani, Bianca Maria.
Affiliation
  • Cataldo ML; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  • De Placido P; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  • Esposito D; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  • Formisano L; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  • Arpino G; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  • Giuliano M; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  • Bianco R; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  • De Angelis C; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  • Veneziani BM; Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy.
Front Oncol ; 13: 1108242, 2023.
Article in En | MEDLINE | ID: mdl-37469415
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Front Oncol Year: 2023 Document type: Article Affiliation country: Italia Country of publication: Suiza
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Front Oncol Year: 2023 Document type: Article Affiliation country: Italia Country of publication: Suiza